Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies

Joshua M. Donaldson, Csaba Kari, Ruben C Fragoso, Ulrich Rodeck, John C. Williams

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Therapeutic antibodies frequently cause side effects by binding antigen in non-target tissues. here we demonstrate a novel molecular design of antibodies that addresses this problem by reversibly "masking" antibody complementarity determining regions until they reach diseased tissues containing disease-associated proteases. Specifically, two distinct single-chain Fv scFv) fragments derived from antibodies against the epidermal growth factor receptor (cetuximab and 425) were fused a protease susceptible linker to their epitopes, which were engineered to encourage intermolecular association. surface plasmon resonance and flow cytometry were used to confirm that the masked complex poorly interacts with native antigen, whereas protease treatment restores antigen recognition. Minimally, the "masked" scFvs possesses an eight-fold lower association with the epitope compared with the individual scFvs unmasked by proteolytic cleavage. This molecular design may have general utility for targeted release of therapeutic antibodies at disease sites.

Original languageEnglish (US)
Pages (from-to)2147-2152
Number of pages6
JournalCancer Biology and Therapy
Volume8
Issue number22
DOIs
StatePublished - Nov 15 2009

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies'. Together they form a unique fingerprint.

  • Cite this